海外の治験の状況「1」での検索結果
224件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients with Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
- Type 2 diabetes mellitus Chronic kidney disease stage 4 MedDRA version: 20.0 Level: LLT Classification code 10076411 Term: Chronic kidney disease stage 4 System Organ Class: 100000004857 MedDRA version: 20.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Brazil, Colombia, Germany, Hungary, Israel, Italy, Mexico, Poland, Romania, Russian Federation, South Africa, Spain, Ukraine, United States
- 2017-07-25
Authorised
- Study to Assess Long term Safety and Efficacy of Current or Prior Treatment with Denosumab in Children/Young Adults with Osteogenesis Imperfecta
- Osteogenesis Imperfecta (OI) br>MedDRA version: 20.0 Level: PT Classification code 10031243 Term: Osteogenesis imperfecta System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
- Australia, Belgium, Bulgaria, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, United Kingdom, United States
- 2018-05-10
Authorised
- A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Georgia, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Russian Federation, Serbia, Slovakia, South Africa, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States
- 2018-03-09
Authorised
- TMC435-TiDP16-C208 - Phase III Trial of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients
- Hepatitis C Virus (HCV) in treatment naïve patients MedDRA version: 14.1 Level: LLT Classification code 10019752 Term: Hepatitis C virus (HCV) System Organ Class: 10022891 - Investigations ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Canada, Germany, Israel, Italy, Mexico, Netherlands, New Zealand, Romania, Russian Federation, Spain, Ukraine, United Kingdom, United States
- 2010-12-06
Authorised
- A study to evaluate whether VX-371 is safe and makes breathing easier in patients with primary ciliary dyskinesia (study also known as CLEAN-PCD or PS-G202)
- Primary Ciliary Dyskinesia br>MedDRA version: 20.0 Level: PT Classification code 10069713 Term: Primary ciliary dyskinesia System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
- Australia, Canada, Denmark, Germany, Italy, Netherlands, Poland, United Kingdom, United States
- 2016-05-19
Authorised
- A long-term follow-up study (ZOE-LTFU) of two studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals’ Herpes Zoster subunit (HZ/su) vaccine and assessment of 1 or 2 additional doses in two subgroups of older adults.
- Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination). MedDRA version: 19.1 Level: LLT Classification code 10019982 Term: Herpes zoster NOS System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Virus Diseases [C02]
- Australia, Brazil, Canada, Czech Republic, Estonia, Finland, France, Germany, Hong Kong, Italy, Japan, Korea, Republic of, Mexico, Spain, Sweden, Taiwan, United Kingdom, United States
- 2016-02-04
Authorised
- A clinical trial to investigate the Efficacy and Safety of TD-1473 for the Treatment of Moderately-to-Severely Active Crohn's Disease
- Moderately-to-Severely Active Crohn’s Disease (CD) MedDRA version: 20.0 Level: LLT Classification code 10013099 Term: Disease Crohns System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Austria, Bulgaria, Croatia, France, Georgia, Germany, Greece, Hungary, Israel, Poland, Portugal, Romania, Russian Federation, Serbia, South Africa, Spain, Ukraine, United Kingdom, United States
- 2018-07-26
Authorised
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS 986165 in Subjects with Moderate-to-Severe Crohn's Disease
- Crohn's Disease MedDRA version: 20.0 Level: PT Classification code 10011401 Term: Crohn's disease System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 20.0 Level: LLT Classification code 10011398 Term: Crohn's System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Brazil, Canada, Czech Republic, France, Germany, Hungary, Italy, Korea, Republic of, Mexico, Poland, Romania, Spain, Taiwan, United Kingdom, United States
- 2018-07-05
Authorised
- A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2- positive advanced (metastatic or locally recurrent) breast cancer
- Advanced breast cancer (metastatic or locally recurrent) MedDRA version: 20.0 Level: PT Classification code 10065430 Term: HER-2 positive breast cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Algeria, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Ecuador, Egypt, Estonia, European Union, Finland, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Lebanon, Lithuania, Mexico, Morocco, Netherlands, Pakistan, Peru, Poland, Portugal, Saudi Arabia, Serbia, Slovenia, Spain, Sweden, Turkey, Ukraine, United Arab Emirates, United Kingdom, Uruguay, Venezuela, Bolivarian Republic of
- 2012-01-16
Authorised
- Study to evaluate 2 types of treatment as first line treatment (masitinib + docetaxel or placebo + docetaxel ) in the treatment of patients with metastatic Castrate Resistant Prostate Cancer (mCRPC)
- metastatic Castrate Resistant Prostate Cancer (mCRPC).;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Canada, China, Czech Republic, Greece, Hong Kong, Hungary, India, Italy, Korea, Republic of, Malaysia, Mexico, Morocco, Peru, Philippines, Poland, Romania, Russian Federation, Singapore, Slovakia, South Africa, Spain, Tunisia, Ukraine, United Kingdom, United States
- 2014-03-26